All In Biotech

Drug Trial Radar · NCT04938817

Safety and Efficacy Study of Investigational Agents as Monotherapy or in Combination With Pembrolizumab (MK-3475) for the Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in Need of Second-Line Therapy (MK-3475-B98/KEYNOTE-B98)

A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)

Last checked: Nov 19, 2026Latest source record: Jun 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 110 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

110

Planned (sponsor's estimate)

Start

Aug 19, 2021

Primary completion

Dec 10, 2029

Study completion Dec 10, 2029

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Daiichi Sankyo
First posted
Jun 24, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a rolling arm study of investigational agents as monotherapy or in combination with pembrolizumab in participants with anti-programmed cell death 1 (PD-1)/ programmed cell death ligand 1 (PD-L1) refractory ES-SCLC in need of second-line treatment. This study will have 2 parts: an initial safety lead-in to determine safety and tolerability for experimental combinations of investigational agents without an established recommended phase 2 dose (RP2D) followed by an efficacy evaluation. Investigational agents will initiate directly in or be added to the efficacy evaluation after an initial evaluation of safety and tolerability of the investigational agent has been completed in a separate study or in the safety lead-in of this study. If an RP2D for a combination being evaluated in the safety lead-in is established from another study, then the efficacy evaluation may begin at the determined RP2D. There will be no hypothesis testing in this study.

Conditions

  • Small Cell Lung Carcinoma

Interventions

  • coformulation pembrolizumab/quavonlimabBiological

    Intravenous (IV) infusion

  • lenvatinibDrug

    Oral administration

  • MK-4830Biological

    IV infusion

  • coformulation favezelimab/pembrolizumabBiological

    IV infusion

  • R-DXdBiological

    IV Infusion

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)Time frame: Up to 21 days in Cycle 1 (Cycle 1 = 21 days)
  2. Number of Participants Who Experience at Least One Adverse Event (AE)Time frame: Up to approximately 60 months
  3. Number of Participants Who Discontinue Study Treatment Due to an Adverse Event (AE)Time frame: Up to approximately 60 months
  4. Objective Response Rate (ORR) Per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1)Time frame: Up to approximately 60 months

Locations

48 sites in 12 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center ( Site 0152)

    Gilbert, Arizona

  • Northside Hospital-Northside Hospital Oncology Network ( Site 0156)

    Atlanta, Georgia

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0180)

    Fort Wayne, Indiana

  • Baptist Health Lexington-Research ( Site 0158)

    Lexington, Kentucky

  • University of Kentucky Chandler Medical Center-Medical Oncology ( Site 0157)

    Lexington, Kentucky

  • MFSMC-HJWCI-Oncology Research ( Site 0178)

    Baltimore, Maryland

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0172)

    Omaha, Nebraska

  • Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0179)

    Omaha, Nebraska

  • Cleveland Clinic-Taussig Cancer Center ( Site 0166)

    Cleveland, Ohio

  • UPMC Hillman Cancer Center ( Site 0177)

    Pittsburgh, Pennsylvania

  • St Francis Cancer Center-Research Office ( Site 0167)

    Greenville, South Carolina

  • Virginia Cancer Institute ( Site 0169)

    Richmond, Virginia

  • Westmead Hospital-Department of Medical Oncology ( Site 4004)

    Westmead, New South Wales, Australia

  • The Prince Charles Hospital-Oncology Clinical Trials ( Site 4003)

    Brisbane, Queensland, Australia

  • Monash Health-Oncology Research ( Site 4005)

    Clayton, Victoria, Australia

  • Hollywood Private Hospital-Medical Oncology ( Site 4001)

    Perth, Western Australia, Australia

  • Standort Penzing der Klinik Ottakring-Abteilung für Atemwegs-und Lungenkrankheiten ( Site 3101)

    Vienna, Austria

  • Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 3100)

    Vienna, Austria

  • Cross Cancer Institute ( Site 3004)

    Edmonton, Alberta, Canada

  • Princess Margaret Cancer Centre ( Site 3003)

    Toronto, Ontario, Canada

  • St. Marys Hospital Center ( Site 3000)

    Montreal, Quebec, Canada

  • Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 3800)

    Szolnok, Jász-Nagykun-Szolnok, Hungary

  • Rambam Health Care Campus-Oncology ( Site 3600)

    Haifa, Israel

  • Shaare Zedek Medical Center-Oncology ( Site 3602)

    Jerusalem, Israel

  • Meir Medical Center. ( Site 3601)

    Kfar Saba, Israel

  • Rabin Medical Center-Oncology ( Site 3604)

    Petah Tikva, Israel

  • Sheba Medical Center-ONCOLOGY ( Site 3603)

    Ramat Gan, Israel

  • Ospedale San Raffaele-Oncologia Medica ( Site 3303)

    Milan, Italy

  • Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 3304)

    Milan, Italy

  • Humanitas-U.O di Oncologia medica ed Ematologia ( Site 3301)

    Rozzano, Milano, Italy

  • ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 3300)

    Siena, Tuscany, Italy

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier ( Site 3900)

    Warsaw, Masovian Voivodeship, Poland

  • Warminsko-Mazurskie Centrum Chorob Płuc w Olsztynie ( Site 3903)

    Olsztyn, Warmian-Masurian Voivodeship, Poland

  • Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 3704)

    Saint Petersburg, Russia

  • Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 3708)

    Krasnoyarsk, Krasnoyarsk Krai, Russia

  • Saint-Petersburg City Clinical Oncology Dispensary-Department of chemotherapy ( Site 3702)

    Saint Petersburg, Leningradskaya Oblast', Russia

  • GBUZ LOKB-Oncology department #1 ( Site 3701)

    Saint Petersburg, Sankt-Peterburg, Russia

  • GBUZ "SPb CRPCstmc(o)" ( Site 3705)

    Saint Petersburg, Sankt-Peterburg, Russia

  • N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( Site 3703)

    Saint Petersburg, Sankt-Peterburg, Russia

  • Seoul National University Hospital ( Site 4101)

    Seoul, South Korea

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.